Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

Last updated: June 14, 2022
Sponsor: PETHEMA Foundation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Leukemia

Treatment

N/A

Clinical Study ID

NCT01376427
LAL-07OPH
  • Ages > 55
  • All Genders

Study Summary

This study proposes to provide adequate treatment and is based on current scientific evidence for elderly patients with ALL Bcr / Abl positive.

To determine whether low-dose chemotherapy associated with imatinib or dasatinib has acceptable tolerability in elderly patients.

To determine whether this association can increase the rate and quality of referrals to the results of the literature of imatinib as monotherapy for elderly patients

Eligibility Criteria

Inclusion

Inclusion Criteria: Adults over 55 years diagnosed with acute lymphoblastic leukemia Ph 'positive (Bcr / Ablpositive) and previously untreated

Exclusion

Exclusion Criteria:

  1. Other LAL negative for t (9; 22) and Bcr / Abl.
  2. biphenotypic acute leukemias or bilinear with t (9; 22).
  3. blast crisis of chronic myeloid leukemia progression during or after polychemotherapytreatment (including allo-BMT) or with inhibitors of tyrosine kinases. The criteria for exclusion from treatment (but not patient record) any of thefollowing
  4. General condition affected (grades 3 and 4 WHO scale), not attributable to the LAL.
  5. Lack of consent by the patient to use their clinical d

Study Design

Total Participants: 100
Study Start date:
January 01, 2007
Estimated Completion Date:
December 31, 2022

Study Description

Prephase (days -5 to -1) Dexamethasone 10 mg/m2 bolus day EV for 5 days (-5 to -1).

Intrathecal treatment (diagnosis and prophylactic / therapeutic) -5 days:

Methotrexate 12 mg

Systemic treatment:

  • Imatinib 400 mg daily and continuous VO.

  • Vincristine (VCR) 1 mg (absolute dose) EV 1, 8, 15 and 22.

  • Dexamethasone (DEX): 10 mg/m2 EV, IM or PO days 1-2, 8-9 days 15-16, 22-23. .

Intrathecal chemotherapy:

Triple therapy was administered with methotrexate (MTX), cytosine arabinoside (ARA-C) and hydrocortisone, days 1, 8, 15 and 22 (five doses total prophylactic between prophase and induction):

MTX 12 mg ARA-C 40 mg Dexamethasone 4 mg

Maintenance during the first year will start after full recovery after induction and after complete reassessment of the disease (including mielograma and Bcr-Abl/Abl or Bcr-Abl/Gus ratio in peripheral blood) and will last until one year from the time of complete remission.

The basic treatment included imatinib 400 mg / day (or dasatinib), mercaptopurine at doses of 50 mg/m2 PO day and methotrexate 20 mg/m2 IM weekly.

One week every 3 months maintenance treatment added a "mini-reinduction" consisting

  • VCR: 1 mg (absolute dose), i.v., day 1.

  • Dexamethasone 40 mg / day, i.v. or p.o., days 1-2.

  • not considered more doses of triple intrathecal therapy. Reinduction only be practiced during the first year after remission, so a total of 4 quarterly.

Maintenance treatment of second year

After the first year of maintenance will perform a complete reassessment of the disease (including myelogram) and if the patient remains in complete remission maintenance will continue (without reinduction) until two years from the time of diagnosis.

Maintenance treatment of third year During the third year after complete remission imatinib administered alone (or dasatinib

Connect with a study center

  • Hospital Germans Trias i Pujol and all Hospital Pethema

    Badalona, Barcelona
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.